1. Home
  2. SAIC vs CRNX Comparison

SAIC vs CRNX Comparison

Compare SAIC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

SAIC

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

HOLD

Current Price

$101.84

Market Cap

4.3B

Sector

Technology

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$35.48

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAIC
CRNX
Founded
1969
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
3.9B
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
SAIC
CRNX
Price
$101.84
$35.48
Analyst Decision
Hold
Strong Buy
Analyst Count
8
8
Target Price
$110.50
$76.75
AVG Volume (30 Days)
554.8K
850.3K
Earning Date
06-01-2026
05-07-2026
Dividend Yield
1.56%
N/A
EPS Growth
7.39
N/A
EPS
2.61
N/A
Revenue
$7,262,000,000.00
$1,039,000.00
Revenue This Year
N/A
$720.10
Revenue Next Year
$1.65
$184.67
P/E Ratio
$39.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$81.08
$25.83
52 Week High
$123.41
$57.99

Technical Indicators

Market Signals
Indicator
SAIC
CRNX
Relative Strength Index (RSI) 42.22 51.40
Support Level $92.46 $33.15
Resistance Level $115.25 $44.89
Average True Range (ATR) 4.85 1.56
MACD -1.38 0.33
Stochastic Oscillator 4.06 79.51

Price Performance

Historical Comparison
SAIC
CRNX

About SAIC SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the Department of Defence (DoD) and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: